Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMC119-06 in acute ischemic stroke
NCT04097652Phase 1Recruiting
- Sponsor
- Meridigen Biotech Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umc119-06 in ischemic stroke, sponsored by Meridigen Biotech Co., Ltd. Primary endpoint: Incidence and frequency of adverse events at 3 months. Started Dec 2019; status: recruiting.
02
Drugs
umc119-06
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04097652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097652.